These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.

Researchers aim to validate the AI tool SCORPIO in prospective studies and eventually seek FDA clearance to sell it as a commercial tool in the US.

The firm will use the funds to further develop its AI-driven image analysis solutions, which extract actionable information from CT, PET, and MRI scans.

Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.

Patients on the firm's SSTR-targeted radiopharmaceutical had improved progression-free survival compared to patients on an mTor inhibitor in a Phase III trial.

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.